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Key points:
 § This publication reviews how a number of 
factors impact on the diversity and content of 
products and forms of cannabis available in 
Europe. Drivers of change in this area include 
policy developments in Europe and elsewhere; 
advances in production and extraction 
techniques; and consumer interest.
 § Understanding and monitoring trends in the 
composition of cannabis products available to 
European consumers is important, as it is likely 
to both be associated with the attractiveness 
of different products to consumers and have 
implications for associated health risks.
 § This analysis focuses on cannabinoids (such as 
∆9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD)), which are synthesised by/in the cannabis 
plant. THC is the most important component 
of cannabis in relation to its attractiveness for 
recreational use, although consumer interest in 
CBD is growing, both because it is considered 
to have some beneficial effects and because it 
may moderate some of the less desirable effects 
associated with THC consumption.
 § In recent years, various synthetic cannabinoids 
have appeared in Europe and complicate further 
analysis in this area. Some of these are now 
controlled internationally and national legislation 
in some countries also restricts the use of 
synthetic cannabinoids or specific synthetic 
cannabinoids. While synthetic cannabinoids 
mimic to some extent the action of THC in the 
brain, they should be distinguished from natural 
cannabis-based products. This is because they 
may sometimes be associated with both greater 
and different health risks.
 § Analysis shows that THC concentrations 
have risen in European cannabis. Recently, 
this increase has been most pronounced for 
cannabis resin. For herbal cannabis, increases in 
potency have been associated with the growth in 
domestic production, under intensive conditions, 
within the EU. For cannabis resin, changes in 
THC concentrations have been attributed to 
the introduction of strains of cannabis plants in 
Morocco producing high levels of THC, although 
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other factors may have also played a part in this 
development.
 § Advances in extraction techniques can be, 
and are now being, used to produce extremely 
high-potency products known as cannabis 
concentrates.
 § Cannabis can also be prepared in edible form 
and may be sold in this form ready for use. The 
prevalence of concentrated and edible cannabis 
products has increased in legal markets in 
the United States, which may indicate that 
similar trends could arise as regulated medical 
(and potentially recreational) use of cannabis 
gains traction in Europe. However, it should be 
recognised that the regulatory frameworks in the 
United States and Europe are markedly different.
 § Monitoring developments in the area of cannabis 
is also complicated because the number of 
cannabis-based medical and health-orientated 
products has expanded. These include products 
manufactured to pharmaceutical quality 
standards, and others with varied composition 
and product descriptions. Some of these may 
potentially be confused with forms of cannabis 
available on the illicit drug market.
 § Recently, cannabis products with very low levels 
of THC have also appeared on the market in 
some European countries based on the argument 
that the THC concentrations are so low that they 
are not restricted by drug control regulations. 
These can be sold as foodstuffs, healthcare 
products and cosmetics. CBD oils have recently 
been marketed as ‘food’ supplements and these 
oils may also contain THC, although usually at 
low concentrations.
 § Overall, the dynamic nature of the current 
cannabis market and diversification of cannabis 
products available gives rise to considerable 
challenges for existing monitoring approaches. 
Sound information on the nature of the 
cannabis available to European consumers 
is important for policy and regulatory 
discussions. In addition, new forms of cannabis 
have the potential to impact on the public 
health consequences of cannabis use; the 
attractiveness of cannabis products to users; 
and regulation across a range of complex 
policy areas. There is therefore an urgent need 
to both improve the conceptualisation of the 
cannabis market for monitoring purposes and 
develop a comprehensive set of tools that are 
commensurate with the growing needs in  
this area.
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I  Introduction
This paper provides an overview of established and emerging 
cannabis products in Europe. For each type of product, 
major issues in its production, distribution, use and effects 
on health are detailed. In doing so, the paper seeks to inform 
a discussion of the new challenges that may emerge in the 
monitoring of these products and the consequences of their 
use. At the time of writing, regulated markets for recreational 
cannabis had yet to emerge in Europe, though the policy in 
some countries in the Americas is rapidly shifting towards the 
legalisation of the recreational and medical use of cannabis. It 
is therefore timely to provide an overview of the diversification 
of cannabis products in Europe, to contribute to the available 
knowledge on cannabis market changes and their implications 
for policy and practice. While there are other aspects of 
relevance, including the modus operandi of organised crime 
groups and traffickers, prevalence and other consumption 
metrics, these are not addressed in this report, as detailed 
information is provided in other European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) publications.
Cannabis is by far the most widely used illicit drug in the 
European Union (EU), accounting for 38 % of all money spent 
on the illicit drug retail market (EMCDDA and Europol, 2016). 
Among adults (aged 15-64), it is estimated that 24.7 million 
(7.4 %) have used cannabis in the last year (EMCDDA, 
2019). The two main cannabis products used in Europe are 
herbal cannabis (marijuana) and cannabis resin (hashish). In 
Europe, these are typically smoked in joints (rolled cigarettes) 
containing tobacco (Hindocha et al., 2016).
The cannabis plant synthesises at least 144 unique 
compounds known as cannabinoids (1) (Hanuš et al., 2016). 
The most abundant of these is ∆9-tetrahydrocannabinol (THC). 
THC produces the effects that people who use cannabis seek 
from the drug, such as feeling ‘high’ and relaxed with changes 
in the perception of colours and sounds. THC can also cause 
unwanted effects such as memory impairment, anxiety and 
paranoia. These adverse effects become more severe with 
higher doses of THC. Concentrations of THC in cannabis 
products have risen in recent years, and evidence suggests 
that users only partially adapt to changes in THC (Curran et al., 
2016). As a result, people who use cannabis may have been 
exposed to rising doses of THC over time. These changes may 
have increased the level of adverse health effects related to 
cannabis use. In Europe, the number of first-time admissions 
to drug treatment for cannabis problems increased by 76 % 
from 2006 to 2017 (EMCDDA, 2019). It is possible therefore 
that an increase in the concentration of THC in cannabis is 
associated with this increase in admissions to treatment 
(1) Here the term ‘cannabinoid’ is used to refer to those synthesised by/in the 
cannabis plant, or phytocannabinoids. These differ from synthetic forms of 
THC (e.g. dronabinol) and from synthetic cannabinoid receptor agonists, or 
‘synthetic cannabinoids’, which are discussed later in this report.
(Freeman et al., 2018). However, conclusions in this regard 
need to be made with caution, as other factors — such as a 
greater awareness of cannabis-related treatment needs, an 
overall increase in the level of provision and changes in referral 
practice, including direct referrals from the criminal justice 
system in some countries — could also explain this increase.
Cannabidiol (CBD) is typically the second-most abundant 
cannabinoid produced by/in the cannabis plant. CBD is non-
intoxicating and has shown promise as a treatment for several 
medical conditions including epilepsy, psychosis and anxiety 
disorders (Bergamaschi et al., 2011; Devinsky et al., 2017; 
McGuire et al., 2017; EMCDDA, 2018b). CBD has been found 
to offset some of the harmful effects of THC, such as memory 
impairment and paranoia, without influencing the ‘high’ sought 
by users (Englund et al., 2017). Some evidence also suggests 
that the balance of THC to CBD may contribute to the level 
of harm experienced from long-term cannabis use. While 
frequent use of cannabis with high THC to CBD ratios has been 
associated with a greater risk of psychosis and dependence, 
it has been argued that this is less commonly observed with 
the use of cannabis with a more balanced THC to CBD ratio 
(Di Forti et al., 2015; Freeman and Winstock, 2015). It has also 
been suggested that encouraging the use of cannabis with a 
more balanced THC to CBD ratio may therefore be a strategy 
for harm minimisation (Englund et al., 2017).
THC and CBD are both synthesised by/in the cannabis plant 
in the glandular trichomes. These structures are resinous 
and sticky, helping to defend the plant against herbivores 
and environmental stresses. They differ from non-glandular 
trichomes, which occur in either cystolithic (found on the upper 
surface of the cannabis leaves) or non-cystolithic (appearing 
mainly on the lower side of the leaves and bracts) form. 
Capitate-stalked trichomes (Figure 1) are most abundantly 
distributed around the female flowers and produce the highest 
quantity of cannabinoids (Turner et al., 1978). Maximising 
the production of these capitate-stalked trichomes (and/
or improving the efficiency of extracting THC from them) 
is a key method for increasing the potency (2) of cannabis 
products. Bulbous trichomes are also glandular but are smaller 
in size and produce fewer cannabinoids. In addition to the 
cannabinoids, glandular trichomes also contain essential oils 
known as terpenes, which give cannabis its distinctive odour. 
Variations in the terpene profile affect the experience of using 
cannabis by influencing its taste and smell, and may influence 
its pharmacological effects (Russo, 2011).
(2) In pharmacology, ‘potency’ is often related to the amount (dose) of the drug 
required to produce an effect. Therefore, using ‘potency’ to describe the 
concentration of THC in cannabis products is not technically correct. A more 
accurate term would be ‘strength’, which is the amount of THC in a defined 
unit of the product. However, for consistency with previous publications and to 
allow comparison with other studies the term ‘potency’ is used throughout this 
report.
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I  Herbal cannabis
The flowers of female cannabis plants contain the greatest 
density of capitate-stalked glandular trichomes and therefore 
the highest concentration of cannabinoids. For this reason, the 
flowers of female cannabis plants are preferentially harvested 
and dried to produce herbal cannabis. Leaves contain low 
concentrations of cannabinoids, while other parts of the plant, 
such as the stem, seeds and roots, contain minimal or no 
cannabinoids. After drying, the floral material is removed from 
the stems and is ready for use.
In 2017, there were 440 000 seizures of herbal cannabis 
in the EU, accounting for 40 % of the total number of drug 
seizures in the EU that year (EMCDDA, 2019). In broad terms, 
there appear to be two main types of herbal cannabis in 
European markets, imported herbal cannabis and ‘sinsemilla’ 
or indoor-grown herbal cannabis, produced within the EU. 
While it is recognised that there are a few exceptions to this 
classification, the distinction is sufficiently widespread to 
make these categories valid. Under natural conditions, the 
pollination of female cannabis flowers by male plants results 
in the production of seeds. Herbal cannabis containing 
seeds is typically produced from outdoor-grown landrace (3) 
crops outside the EU. This is referred to here as ‘imported 
herbal cannabis’. Imported herbal cannabis is often heavily 
compressed or vacuum packed after drying to facilitate 
international trafficking, and is typically a dark green to brown 
colour. It may be sold in compressed blocks, as bundles of 
herbal material or as loose plant material containing flowers, 
stems and seeds (Figure 2). Data collected by the EMCDDA 
indicates that the Balkans and Sub-Saharan Africa are major 
sources of imported herbal cannabis (EMCDDA, 2012).
When herbal cannabis is produced under controlled 
conditions, female plants are almost exclusively cultivated in 
the absence of male plants. This process prevents fertilisation, 
enabling female plants to continue flowering for longer and 
to expend additional energy producing more trichomes, 
resulting in a greater concentration of cannabinoids. Herbal 
cannabis produced in this way is referred to as ‘sinsemilla’ 
(from the Spanish words ‘sin’ (without) and ‘semilla’ (seed)); 
it is also known as ‘indoor-grown herbal cannabis’, ‘nederwiet’ 
in the Netherlands and ‘skunk’ in the United Kingdom (4) (see 
Figure 3). This form of herbal cannabis is typically produced 
in the EU and appears to be the most common type of herbal 
cannabis used in the EU. The freshness of the product and the 
high abundance of glandular trichomes results in high levels of 
terpenes creating its strong and distinctive odour.
A number of other factors contribute to the cannabinoid 
profile of herbal cannabis (Potter, 2014). The synthesis of 
THC and CBD is genetically determined, with plants either 
producing high levels of THC, high levels of CBD or a mixture 
of THC and CBD. THC and CBD are synthesised in the plant 
from a common precursor via distinct biosynthesis pathways, 
which means that CBD production limits the amount of 
THC synthesised and vice versa. As a result, THC-producing 
(3) A landrace is a domesticated, locally adapted, traditional variety of a species 
that has developed over time, through adaptation to its natural and cultural 
environment of agriculture and pastoralism, and as a result of isolation from 
other populations of the species.
(4) ‘Skunk’ is one of many specific hybrid strains of cannabis (others include 
‘White Widow’ and ‘K-2’); however, this term is also used in the United 
Kingdom as a generic name for unfertilised female cannabis flower with high 
concentrations of THC.
FIGURE 1
Both THC and CBD are synthesised and deposited in 
capitate-stalked trichomes on the cannabis plant (top). 
Trichomes help to defend the plant and are abundant in 
the flowering tops of female plants (bottom).
Photos: © David Potter. 
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strains are almost exclusively selected to maximise THC 
yields. Cannabis plants are selectively bred for desirable 
characteristics such as a desirable profile of cannabinoids 
and terpenes (contributing to odour and taste), a high yield 
of cannabis flower and resistance to disease. There are many 
different strains available. An analysis of cannabis samples 
sold in coffee shops in the Netherlands from 2005 to 2015 
found that the most commonly sold strains were ‘White 
Widow’, ‘K-2’, ‘Power Plant’, ‘Amnesia Haze’ and ‘Jack Herrer’; 
all had mean THC concentrations of 16-17 % (Niesink et al., 
2015). The most recent (2016-2017) THC data published by 
the Trimbos Institute showed that domestic herbal cannabis 
(nederwiet) had an average THC concentration of 17 % 
(Rigter and Niesink, 2017). In addition to genetics, optimising 
growing conditions can have marked effects on cannabinoid 
production. Indoor cannabis production facilities therefore 
typically utilise powerful lighting systems, which maintain 
flowering throughout the year by manipulating the length 
of the day-night cycle, and CO
2
 generators, which enhance 
photosynthesis by increasing CO
2
 levels. In addition, fertilisers 
and pesticides are commonly used to promote plant growth 
and prevent damage by mould or insects.
Photos: © Tom Freeman (left) and David Potter (right). 
FIGURE 2
Imported herbal cannabis in a compressed block. 
Photos: © David Potter (left) and Tom Freeman (right). 
FIGURE 3
Sinsemilla is produced by preventing the pollination of female plants, resulting in the production of large flowering tops (left). 
Sinsemilla is typically sold in the form of whole flower (right). 
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I  Changes in the potency and price of herbal cannabis
Data collected by the EMCDDA (Figure 4) show that the 
potency of herbal cannabis in Europe doubled from an 
estimate of 5 % to 10 % THC from 2006 to 2016 (Freeman et 
al., 2019). There was also an increase in the price of herbal 
cannabis from an estimated EUR 7 to EUR 12 per gram 
(Freeman et al., 2019). This upwards trend was still evident 
after adjusting for inflation according to the Harmonised 
Indices for Consumer Prices (Eurostat, 2018).
Country-specific studies have also reported changes in herbal 
cannabis products. For example, the Trimbos Institute reported 
increases in cannabis potency in the Netherlands from 2000 to 
2004: the potency of nederwiet rose from 9 % to 20 % THC and 
the potency of imported herbal cannabis rose from 5 % to 7 % 
THC (Pijlman et al., 2005). However, from 2005 to 2017 the 
potency of nederwiet decreased marginally, from 18 % to 17 % 
THC, and the potency of imported herbal cannabis remained 
at the same level, around 7 % THC (Niesink et al., 2015; Rigter 
and Niesink, 2017). Surveys in the United Kingdom found that 
the potency of both imported herbal cannabis and sinsemilla 
were similar in 2004/2005 and in 2016, but that the market 
share of sinsemilla increased from 51 % in 2005 to 94 % in 
2016, increasing the mean potency of all cannabis products 
seized (Potter et al., 2008, 2018). Studies in France and Italy 
also found that increases in the potency of herbal cannabis are 
partly attributable to an increased market share of sinsemilla 
relative to imported herbal cannabis. While not routinely 
tested, the ratio of cannabinol to THC provides an indication 
of the freshness of the cannabis, which may be useful for 
assessing domestic cultivation dynamics in Europe (Zamengo 
et al., 2014, 2015; Dujourdy and Besacier, 2017). Increases in 
the market share of sinsemilla may account for the observed 
increase in THC content at the European level.
I  Cannabis resin
In addition to herbal cannabis, plant material can be used to 
produce cannabis resin. This can create products with higher 
THC concentrations than herbal cannabis preparations, 
increasing the value of the products relative to their weight. 
Cannabis resin is typically brown in colour and is compressed 
into bars, balls or other shapes. This facilitates trafficking by 
allowing relatively large quantities of the drug with a high 
retail value to be concealed in smaller packages than would 
be the case for herbal cannabis. Moreover, cannabis resin 
may not have the strong and distinctive odour of sinsemilla, 
reducing the risk of detection. These factors, together with 
consumer preferences in some countries, make cannabis 
resin a desirable product for international drug trafficking. In 
2017, there were 311 000 seizures of cannabis resin in the 
EU, accounting for 28 % of all drug seizures (EMCDDA, 2019). 
Although there are currently a greater number of seizures of 
herbal cannabis than of cannabis resin, the total quantity of 
resin seized (424 tonnes) in 2016 exceeded that of herbal 
cannabis (124 tonnes).
FIGURE 4
Changes in the potency and price of herbal cannabis in Europe, 2006-2016. 
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Note: Data show means (+/- 95 % confidence intervals) for estimated trends after accounting for variation across countries. Expected changes based on inflation of 
consumer goods are shown in red circles.
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Morocco is believed to be the largest producer of cannabis 
resin for export to European markets. Trafficking routes into 
Europe include Spain, Portugal and eastwards along the 
Mediterranean Sea. The Netherlands is a major distribution 
point for Moroccan resin throughout Europe (including to 
Denmark, Germany and the United Kingdom) and beyond 
(Russia and Belarus). Resin produced in Afghanistan is also 
trafficked directly to the United Kingdom from south-west Asia 
(EMCDDA, 2017a). Resin produced in Lebanon, though less 
frequently encountered, may also be trafficked into Europe. 
In addition, there is also now some evidence of the limited 
domestic production of cannabis resin within Europe (Chouvy, 
2016).
Traditional methods of resin production include the ‘rubbing 
method’ (Figure 5), typically used in south-west Asia and 
the Himalayas, and the ‘sieving method’, used in Morocco, 
Afghanistan and Pakistan, and domestically within Europe. 
Manicure waste from the plant or ‘trim’ is often used for 
sieving, but sinsemilla can be used to produce a higher 
potency product. In addition to screens, alternative devices 
can be used for sieving such as a rotating drum or ‘pollinator’. 
When using the sieving method, the efficiency of extraction 
can be improved by including additional stages in the process 
such as freezing the plant material or processing it with 
icy water/dry ice (solid carbon dioxide). This hardens the 
trichomes, allowing their heads to be easily removed and 
increasing the potency of the extracted product (Figure 6).
Photos: © David Potter. 
FIGURE 5
Traditional resin production using the ‘rubbing method’.  The flowers of female cannabis plants are rubbed between the hands, 
depositing the sticky resinous trichomes. Resin produced in this way is often called ‘charas’. 
FIGURE 6
Exposing cannabis plant material to cold temperatures can increase the efficiency of extraction. Cannabis is placed in icy 
water and aggravated using a food processor to remove the trichomes (1) before sieving (2). Dry ice can also be used to 
remove the trichomes (3) before sieving (4).  
Photos: © David Potter. 
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I  Changes in potency and price of cannabis resin
European cannabis resin is a highly variable product. Resin 
produced from landrace crops can have a relatively low 
concentration of THC with a balanced quantity of CBD. Newer 
products often contain high concentrations of THC and limited 
CBD. It is not possible to estimate the potency of resin on the 
basis of its appearance (Figure 7).
Data collected by the EMCDDA indicate that the potency of 
cannabis resin in Europe has increased substantially in recent 
years (Freeman et al., 2019). As shown in Figure 8, the potency 
of resin remained relatively stable from 2006 to 2011 (8-
10 % THC) before rising more sharply to 17 % in 2016. While 
trends in THC concentrations have been monitored in Europe, 
EMCDDA data collection on CBD content is not currently 
standard. Therefore, trends in CBD content at European level 
are uncertain at present. From 2006 to 2016, the price of 
cannabis resin increased, from approximately EUR 8 to EUR 12 
per gram.
The timing of these changes is notably similar to that reported 
in a 25-year monitoring study (1992-2016) of cannabis 
samples in France (Dujourdy and Besacier, 2017). That 
study found that THC concentrations in resin increased 
from 2000 onwards, and from 2011 THC concentrations 
increased substantially. From 2011 to 2016, the potency of 
cannabis resin in France rose from a mean of 12 % to 23 % 
THC. However, concentrations of CBD remained stable at 
approximately 4 % throughout the 25-year period. The authors 
Note: The THC concentrations of each product are shown in red, and the CBD 
concentrations are shown in blue.
Source: Potter et al., 2018. 
Photo: © David Potter. 
FIGURE 7
Cannabis resin samples from police seizures in England, 2016. 
FIGURE 8
Changes in potency and price of cannabis resin in Europe, 2006-2016. 
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attributed the increase in THC to the emergence of a new 
type of Moroccan resin (mean of approximately 26 % THC) 
replacing traditional resin (mean of approximately 13 % THC). 
This has also been evidenced by cannabis resin seized in 
Morocco (Stambouli et al., 2016). Similar results were found 
in Denmark, where the THC concentration of resin increased 
marginally from 8 % THC in 2000 to 11 % THC in 2011, 
followed by a marked increase to 25 % THC between 2011 and 
2017 (Rømer Thomsen et al., forthcoming). During this period, 
CBD concentrations in resin remained relatively stable at 6 %. 
This resulted in an increase in the THC to CBD ratio over time. 
Studies in Italy and the United Kingdom have also reported 
increases in the THC concentrations and in the THC to CBD 
ratios of resin samples in recent years (Zamengo et al., 2014, 
2015; Potter et al., 2018).
Fieldwork conducted in Morocco suggests that these changes 
may be attributable to the introduction of new strains of 
cannabis with higher yields and greater potency, replacing 
the landrace ‘kif’ plants previously used for resin production 
(Chouvy and Afsahi, 2014). In the past, Moroccan cannabis 
resin was typically produced in 9-ounce (250-gram) bars 
known as ‘soap bars’ or ‘savonettes’ (Figure 9). The left image 
shows a ‘soap bar’, weighing 230 g. The potency of this resin 
was 3.7 % THC, resulting in a total of 8.5 g of THC. The right 
image shows a 15-gram ball of resin at 58 % THC, amounting 
to a similar quantity of THC (8.7 g).
European police services have recently reported an increase 
in seizures of resin in new quantities and shapes, including 
200-gram melon-shaped balls, 100-gram tablets and 10-gram 
olive-shaped pellets (Chouvy, 2016). It is unclear whether 
these changes are attributable to new resin production 
methods and/or an attempt to create products with a different 
appearance.
Changes in resin production methods in Morocco may have 
been driven by the relatively low potency and poor reputation 
of Moroccan resin among European consumers, and increased 
competition because of domestically produced sinsemilla 
within Europe (EMCDDA, 2017a). At the European level, 
it is evident that recent increases in potency have been 
substantially greater for cannabis resin (from 8 % to 10 % 
THC in the 2006-2011 period to 17 % in 2016) than for herbal 
cannabis (from 5 % THC in 2006 to 10 % THC in 2016). 
Moreover, recent increases in price have been less pronounced 
for cannabis resin, from approximately EUR 8 to EUR 12 per 
gram between 2006 and 2016, than for herbal cannabis, 
from an estimated EUR 7 to EUR 12 per gram from 2006 
to 2016. Data limitations need to be recognised, however, 
which may influence the accuracy and representativeness of 
these estimates. First, the use of police seizures for obtaining 
cannabis products and police surveys for estimating price 
may result in sampling bias. This is a limitation common to 
cannabis monitoring exercises in most countries and areas, 
although in the Netherlands it has been possible to sample 
directly from the market place (Niesink et al., 2015). Second, 
data collection methods across countries may differ. This 
issue persists even though data reporting tools have been 
improved and harmonised to improve the accuracy, reliability 
and comparability of data collected on European drug markets 
(EMCDDA, 2017c). Third, annual data for each cannabis 
product were not consistently available for each of the 28 EU 
Member States, Norway and Turkey. However, the statistical 
techniques used improve the handling of missing data and 
increase the generalisability of the analysis undertaken (see 
Freeman et al., 2019).
These changes in potency and price appear to have affected 
the relative value of herbal cannabis and cannabis resin. 
When combining information on potency and price, the 
quantity of THC for every euro spent on herbal cannabis was 
similar in 2006 (13 mg THC per euro) and 2016 (13 mg THC 
per euro). This suggests that herbal cannabis has remained 
relatively stable in terms of value for money during this time. 
For cannabis resin, value remained stable at 11 mg THC per 
euro between 2006 and 2011, before increasing to 16 mg 
THC per euro in 2016 (Figure 10). This suggests that cannabis 
resin became a better-value product between 2006 and 2016, 
driven by a larger increase in potency relative to price between 
2011 and 2016. It may be the case that the introduction of new 
cannabis strains in Morocco has enabled producers to create 
a better-value resin product, and that these savings have been 
passed on to European consumers. As a result, cannabis resin 
may now be a more attractive product to some European 
consumers because of its higher potency and better value for 
money than herbal cannabis (Freeman et al., 2019).
It is important to remember that information on the source of 
cannabis products may not be reliable, and informants have 
suggested that some ‘Moroccan’ resin may have actually been 
FIGURE 9
Traditional and new forms of resin production.
Photos: © David Potter. 
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produced in Europe and sold as a Moroccan product (Chouvy, 
2016). The appearance of resin does not provide reliable 
information about the source of production. It is rarely possible 
to determine the origins of seized resin with certainty, and, now 
that Moroccan producers appear to be using plants originating 
in Europe, verifying the classification of resin as Moroccan is 
even more challenging. Although a number of sources suggest 
that the plants used to produce Moroccan resin have changed, 
information on the methods used to produce resin in Morocco 
also remains limited. Some informants have argued that the 
traditional ‘sieving method’ would not be efficient enough to 
produce the high concentrations of THC recently found in 
European resin samples, and that newer methods including 
those involving freezing, icy water or dry ice may have been 
used (Chouvy, 2016).
I  Concentrated extracts of cannabis
In addition to resin production, there are several other methods 
for extracting cannabinoids from plant material. The methods 
of resin production previously described involve the physical 
removal of the trichomes, which removes the cells and basal 
structure of the trichome heads as well as their secretions. 
In the process, trichome stalks and leaf fragments are 
unintentionally captured in these crude sieving processes. 
Greater efficiency can be achieved through the use of solvents 
or gases. These methods can achieve significantly higher 
potencies by extracting only the resinous secretions from 
trichome cells. Concentrated extracts of cannabis are often 
consumed by ‘dabbing’, in which a small quantity is applied 
to a ‘nail’ after heating with a blowtorch, and the smoke is 
inhaled through a waterpipe. As a result of the high levels of 
THC exposure, cannabis concentrates may be associated with 
greater dependency and more mental health problems than 
standard cannabis products (Chan et al., 2017; Meier, 2017).
One method of extraction uses liquefied butane gas to produce 
concentrated extracts ranging from 70 % to 80 % THC, known 
as ‘butane hash oil’ or ‘BHO’ (Figure 11).  
FIGURE 10
Changes in the value of herbal cannabis and cannabis resin, reflecting the quantity of THC for every euro spent on cannabis 
from 2006 to 2016.
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FIGURE 11
Production of butane hash oil. Ground cannabis flower 
is packed into a tube. Butane is passed through the tube 
and collected in a tray below. This liquid is then heated or 
‘purged’ to evaporate the butane.
Photo reproduced from Varlet (2016) under the Creative Commons License 
(CC BY 4.0). 
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To produce BHO, ground cannabis flower may be packed into 
a sealed tube with a fine mesh covering the base. Butane is 
added from a compressed canister fitted to the top of the 
tube and is collected in a tray under the base. The solution is 
then evaporated through heating to produce the final product 
(this is sometimes referred to as ‘purging’). Depending on the 
solvent used and the method of purging, the finished product 
can vary in consistency (Figure 12). For example, ‘shatter’ is 
hard and brittle, ‘wax’ resembles a soft wax and ‘crumble’ is 
soft and flaky.
The use of highly flammable solvents such as butane can carry 
significant risks. There have been numerous press reports of 
explosions caused by this method in Europe, some of which 
resulted in injury or death. Other methods of extraction include 
closed-loop systems that minimise the chance of gas ignition, 
and other relatively safe extraction methods such as those that 
use supercritical CO
2
. However, these require the use of more 
advanced and expensive technical equipment, which might 
be more commonplace in large-scale commercial production 
sites (e.g. for licit sale in the United States or Canada) than 
in smaller illicit production sites typically detected in Europe. 
Another concern with solvent-based extractions is the adverse 
health effects of solvent residues, which often remain in the 
final product. A study of 57 cannabis concentrate samples in 
the United States found that 83 % contained solvent residues, 
most commonly isopentane (Raber et al., 2015).
Another new method for producing concentrated extracts 
involves the application of heat and pressure to cannabis 
material to create a concentrated extract known as ‘rosin’. This 
method may be desirable, as it removes the risk of explosion 
and produces no solvent residue. Rosin production techniques 
are more accessible, as they can be achieved using simple 
household materials (hair straighteners and greaseproof 
paper). Rosin is reported to have similar potencies to butane 
hash oil (approximately 70-80 % THC). 
Concentrated extracts are typically brown to yellow in colour 
and reach up to 80 % THC content, with minimal CBD (Raber 
et al., 2015). However, it is possible to separate out these 
products further using distillation. This can create high-potency 
clear crystalline products or ‘distillates’. Examples of these 
products can be seen on sale in the United States (Figure 13). 
Distillation can also be used to make highly concentrated 
liquids and cartridges used for vaping (Caulkins et al., 2018).
European data on cannabis concentrates are limited at 
present. However, recent data in the United States may 
provide an indicator of emerging trends. An analysis of sales 
data in a new legal market in Washington state found that, 
within only 2 years (2014-2016), cannabis concentrates grew 
FIGURE 12
Cannabis concentrates seized in the United Kingdom (Potter et al., 2018). The shatter sample (left) contained 79 % THC and 
the crumble sample (right) contained 83 % THC.
Photos: © David Potter. 
FIGURE 13
Crystalline forms of THC extract
Photo: © iStock. 
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to constitute 21 % of all sales and contained a mean THC 
content of 69 % (Smart et al., 2017). Furthermore, data from 
illicit seizures across the United States demonstrate a marked 
increase in the proportion of concentrated hash oil samples 
seized (0.5 % to 4.7 % of all cannabis samples) and their mean 
THC concentration (6.7 % to 55.7 % THC) from 2008 to 2017 
(Chandra et al., 2019).
A study of cannabis samples seized by five UK (English) police 
constabularies in 2016 (Potter et al., 2018) reported two 
samples of hash oil (51 % THC and < 1 % CBD) and a small 
number of butane hash oil samples (ranging from 73 % to 83 % 
THC, with < 1 % CBD). No samples of this kind were found in 
previous surveys of cannabis samples conducted in England 
and Wales in 2008 (Hardwick and King, 2008) or in 2004-2005 
(Potter et al., 2008). Concentrated extracts or oils have not 
been reported in forensic studies conducted in Italy (Zamengo 
et al., 2014, 2015) or France (Dujourdy and Besacier, 2017) 
and, because of restrictions on their sale, did not form part of 
the standardised purchasing protocol used in Dutch coffee 
shops by the Trimbos Institute (Pijlman et al., 2005; Niesink et 
al., 2015). Given the lack of information on these new products, 
it would be wise to include and specifically target cannabis 
concentrates in future European data collection exercises 
aimed at establishing patterns of cannabis use and in the 
analysis of data from drug seizures.
I  Edibles
Another important type of cannabis products are ‘edibles’, 
an umbrella term referring to foods, often sweets or liquids, 
containing THC and/or CBD for oral administration. The 
addition of cannabis products to foodstuffs results in slower 
absorption and a longer duration of effects than inhalation. 
For this reason, careful dosing is especially important. In the 
United States, there is a limit of 10 mg THC per serving or 
recommended unit in Colorado and Washington, and 5mg 
THC in Alaska and Oregon (Gourdet et al., 2017). There is also 
a serious risk of unintentional exposure, as these products 
may be difficult to distinguish from other foods, sweets or 
drinks (Figure 14). Edible cannabis products were found to be 
responsible for 48 % of paediatric emergency hospital visits 
due to cannabis in Colorado in the 2009-2015 period (Wang et 
al., 2016).
There is evidence that edibles currently form a significant and 
probably growing part of licit cannabis markets, representing 
for example approximately 10 % of all sales in Washington 
state (Caulkins et al., 2018). Furthermore, the use of edible 
products is reported to be higher in US states with medical 
cannabis laws than in those without (Borodovsky et al., 2016).
Information about the use of edibles in Europe is limited, but 
the available data suggest that at present this is a rare route of 
administration among European cannabis users (Hindocha et 
al., 2016). On the basis of recent trends in the United States, 
it can be expected that the prevalence of edible products and 
cannabis concentrates might increase in Europe in the future 
as consumers become more aware of innovations taking place 
in licit markets in North America. Moreover, in Europe, there 
has been a recent increase in the availability of cannabis-
based products that contain less than 0.2- 0.3 % THC (see 
below). These are argued to be of such low potency that they 
do not fall under existing drug control regulations. Some of 
these are edibles; however, they may still be considered illicit 
in some countries even though only small amounts of THC are 
present.
FIGURE 14
Edible cannabis products. ‘Pop tarts’ are a breakfast food produced by Kellogg’s (left) ‘Pot tarts’ containing 35 mg THC (right).
Photos: © iStock (left) and Drug Enforcement Administration (right). 
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I  Synthetic cannabinoids
Synthetic cannabinoids are a group of artificially made 
substances that act on the same receptors in the body as 
THC but are usually much more potent. This means that their 
effects can be markedly different from and more powerful than 
cannabis. They were originally developed by scientists to study 
how the body works and to explore the potential of cannabinoids 
as medicines. Since the mid-2000s, entrepreneurs and, 
increasingly, criminal groups have sold plant material mixed 
with synthetic cannabinoids in Europe as ‘licit’ replacements for 
cannabis. The first synthetic cannabinoid detected in Europe 
was JWH-018 in 2008. Since then, more than 180 synthetic 
cannabinoids have been reported to the EMCDDA, making them 
the largest group of new psychoactive substances monitored by 
the EU Early Warning System (EMCDDA, 2019).
Most synthetic cannabinoids in Europe are imported from China 
in powder form. They are then dissolved in solvents such as 
acetone and mixed with plant material to create a product that 
can be smoked. These ‘smoking mixtures’ are sold online, in 
‘head shops’ or on the illicit market and are often packaged with 
brand names such as ‘Spice’, ‘K-2′ or ‘Black Mamba’ (Figure 15) 
or increasingly in unlabelled bags. The brand and the name 
provide no guarantee of its contents, which vary within and 
between batches. More recently, synthetic cannabinoids have 
also been found in products resembling cannabis resin and in 
e-liquids for vaping. The amount of synthetic cannabinoids in 
smoking mixtures varies widely, both within batches and across 
different batches. In addition, mixtures of different synthetic 
cannabinoids may be used in the products. These factors, 
combined with the high potency of the substances, make it 
difficult for users to control the dose that they are exposed to 
and can lead them to unintentionally administer a toxic dose. 
The emergence of synthetic cannabinoids has led to the rapid 
introduction of various legislative approaches to their control in 
Europe.
The prevalence of synthetic cannabinoid use is low among the 
general population according to surveys carried out in Europe 
(EMCDDA, 2017b). While it is thought that many people prefer 
the effects of cannabis over synthetic cannabinoids (Winstock 
and Barratt, 2013), in some areas, these substances have 
developed a reputation as powerful and cheap intoxicants 
among vulnerable groups, such as the homeless and prisoners, 
who use them for their ‘mind-numbing’ effects. As synthetic 
cannabinoids are not included in routine drug testing, some 
people may use them (rather than cannabis or other drugs) 
to avoid detection. This is particularly important in the context 
of road safety, where more research is needed to assess the 
prevalence of use of these substances among drivers and the 
severity of the impairments they cause (EMCDDA and CCSA, 
2018).
The high potency and difficulties that exist in the detection of 
synthetic cannabinoids make them particularly attractive to 
those wanting to smuggle or use drugs in a prison setting. This 
is reflected in data from a survey conducted in nine prisons in 
the United Kingdom, which found that synthetic cannabinoids 
were the most widely used of all drugs (User Voice, 2016). Of 
the 635 people surveyed, 33 % had used synthetic cannabinoids 
in the last month compared with 14 % for cannabis and 8 % for 
heroin. A number of European countries have highlighted the 
role of synthetic cannabinoids in aggravating existing mental 
health conditions or mental states associated with self-harm 
(EMCDDA, 2018c). Severe poisoning is more common with 
synthetic cannabinoids than with cannabis. In some cases, the 
poisoning may even be fatal (Trecki et al., 2015). Sometimes 
these products can cause explosive outbreaks of mass 
poisonings involving dozens or hundreds of people. This is 
because of the high potency of the synthetic cannabinoids as 
well as the large dose that users are exposed to in smoking 
mixtures. For further information on synthetic cannabinoids, see 
the EMCDDA Perspectives on Drugs Synthetic cannabinoids in 
Europe (EMCDDA, 2017b).
I  Cannabis-based medicinal products
There is growing interest in the medical value of cannabis 
and cannabinoids, and these are increasingly becoming 
available as medicines in Europe (see EMCDDA, 2018b). Some 
cannabis-based medicines contain CBD only, and may be used 
to treat specific conditions such as paediatric epilepsy. Other 
cannabis-based medicines contain significant levels of THC 
and/or a combination of THC and CBD. These may be subject 
FIGURE 15
‘Spice’ is one of several products containing synthetic 
cannabinoids added to inert plant material.
Photo: Lance Cpl. Damany S. Coleman/Wikimedia Commons/Public Domain.
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to national legal sanctions unless approved for medical use. 
While medicines containing cannabinoids can resemble other 
medicinal products, some cannabis-based preparations can be 
very difficult to distinguish from illicit cannabis.
The most widely approved cannabis-based medicinal 
product in Europe is Sativex® (nabiximols), an oromucosal 
spray containing equal amounts of THC and CBD derived 
from the cannabis plant. Sativex® has gained approval in 
21 EU countries for the treatment of spasticity in multiple 
sclerosis. The drug first received regulatory approval in 2010 
and is produced by GW Pharmaceuticals (United Kingdom). 
Dronabinol (Marinol®; AbbVie Inc., United States) is a synthetic 
form of THC available in capsule form, which is approved as 
a treatment for nausea and vomiting for patients receiving 
chemotherapy who have failed to respond to conventional 
antiemetics, and as an appetite stimulant for patients with 
HIV/AIDS. Dronabinol is also available in liquid form (Syndros®; 
Insys Development Company, Inc., United States). Another 
cannabinoid approved for medical use is nabilone (Cesamet®; 
Bausch Health, Canada). Nabilone is a synthetic cannabinoid 
similar to THC, available in capsule form and used to treat 
nausea and vomiting for patients receiving chemotherapy who 
have failed to respond to conventional antiemetics.
Epidiolex®, an oral liquid containing 100 mg/ml plant-derived 
CBD developed by GW Pharmaceuticals (United Kingdom) 
is another cannabis-based medicine. In June 2018, it was 
approved by the Food and Drug Administration in the United 
States as a treatment for patients suffering from rare paediatric 
epilepsy syndromes (Dravet and Lennox-Gastaut syndromes). 
As of May 2019, this medicine had not been approved in the 
EU.
Several EU countries allow doctors to prescribe cannabis 
for various conditions. The most commonly used products 
in these countries are those produced by the Dutch medical 
cannabis company Bedrocan. It provides highly standardised 
cannabis varieties, all of which comply with the EU’s good 
manufacturing practice (GMP) standards. This implies that the 
cannabis produced by Bedrocan meets pharmaceutical-level 
quality standards and is consistent from batch to batch in 
terms of cannabinoid content. Currently available products 
include Bedrocan® (22 % THC, < 1 % CBD (see Figure 16)), 
Bedrobinol® (13.5 % THC, < 1 % CBD), Bediol® (6.3 % THC, 8 % 
CBD), Bedica® (14 % THC, < 1 % CBD) and Bedrolite® (< 1 % 
THC, 9 % CBD). Standardised cannabis-based medicines are 
also available from other companies such as Tilray in Canada. 
In addition to standardised herbal cannabis-based medical 
preparations, Tilray produces a number of standardised 
cannabis oils containing varying THC to CBD ratios. These 
include ‘10:10 Balance Oil’ (10 mg/ml THC and 10 mg/ml 
CBD), ‘25:0 Oil’ (25 mg/ml THC) and ‘5:20 Oil’ (5 mg/ml THC 
and 20 mg/ml CBD).
I  Cannabis oils
Although uncommon, high-concentration cannabis oil has 
been available on the illicit drug market for many years. In 
recent years, however, there has been an increase in the 
sale on the high street and online of low-concentration 
THC products. These included a variety of product types 
with one of the more common of these being oils, often 
referred to as ‘cannabis oils’ or ‘CBD oils’ (Figure 17). Broadly 
speaking, cannabis oil is any oil that contains cannabis or 
cannabis compounds, and hence the composition can vary 
greatly depending on what type of cannabis was used in 
the manufacturing process, and whether the final product 
predominantly contains CBD, THC or a combination of both. 
Many CBD oils are manufactured using hemp. Hemp can be 
used to produce oils with high levels of CBD but with THC 
levels remaining below a threshold of 0.2 %. Below this level 
of THC, such oils may potentially not be controlled under drug 
legislation in many EU countries, although national practices 
vary and regulatory approaches differ in this area (EMCDDA, 
2018a). These products are often available as some sort of 
‘health supplement’ or wellness product, although it is often 
unclear on what basis these claims are made. For further 
FIGURE 16
Medicinal cannabis in 5 g containers.
Photo © ncsm.nl.
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information on this complex and rapidly evolving field, please 
refer to the EMCDDA’s recent review of the medical uses of 
cannabis and cannabinoids (EMCDDA, 2018a).
Recent studies testing cannabis oils in Europe found that CBD 
concentrations often differed significantly from those claimed 
and, in addition, some contained THC, which would make them 
illicit in many jurisdictions (Hazekamp, 2018; Pavlovic et al., 
2018).
It should also be noted that there is also a long-established 
market for oils containing much higher concentrations of THC 
(e.g. approximately 50 %). These are available as products 
for medicinal use in some jurisdictions, as described in the 
previous section (Tilray). Although uncommon, these high-
concentration THC products have also existed for many years 
on the illicit drug market. High-concentration THC cannabis 
oils may be attractive from the perspectives of drug trafficking 
because of their high monetary value relative to weight.
I  Conclusions
Cannabis products have become increasingly diverse in 
Europe. This trend may continue, especially if policy changes 
increase the availability of products for medical (and potentially 
recreational) use. It is therefore important to ensure that 
countries capture adequate information with which to monitor 
these products and their effects on health. In particular, it is 
recommended that information about cannabis concentrates 
is gathered at the national and European levels. It would also 
be advisable, from a harm reduction perspective, to monitor 
concentrations of CBD in cannabis. Finally, distinguishing 
cannabis products for recreational use from medical cannabis 
products and unregulated CBD oils will be important for law 
enforcement in many jurisdictions.
FIGURE 17
CBD oils are widely available as health food supplements.
Photo © Tom Whettem.
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